3 March 2025 Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board
28 February 2025 ORYZON announces the voting results of February 2025 Extraordinary General Shareholders' Meeting
27 February 2025 ORYZON reports financial results and corporate update for quarter ended December 31, 2024
14 February 2025 ORYZON announces journal publication of final Phase IIa REIMAGINE results with vafidemstat in Psychiatry and Clinical Neurosciences
23 January 2025 ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
21 January 2025 ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
13 January 2025 ORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with venetoclax and azacitidine clinical trial in first line acute myeloid leukemia